Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710

Blood

Volumn 116, Issue 19, 2010, Pages 3751-3757

  Powell, Bayard L ^a   Moser, Barry ^a   Stock, Wendy ^a   Gallagher, Robert E ^b   Willman, Cheryl L ^c   Stone, Richard M ^a   Rowe, Jacob M ^b   Coutre, Steven ^c   Feusner, James H ^d   Gregory, John ^d   Couban, Stephen ^e   Appelbaum, Frederick R ^c   Tallman, Martin S ^b   Larson, Richard A ^a  

^a Cancer and Leukemia Group B   (United States)

^b Eastern Cooperative Oncology Group   (United States)

^c Southwest Oncology Group   (United States)

^d CHILDREN S ONCOLOGY GROUP   (United States)

^e Canada Clinical Trials Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; MERCAPTOPURINE; METHOTREXATE; RETINOIC ACID;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EVENT FREE SURVIVAL; FEMALE; HUMAN; LOG RANK TEST; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT DURATION;

EID: 77958456360     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-02-269621     Document Type: Article

References (33)

1. Stone RM, Mayer RJ. The unique aspects of acute promyelocytic leukemia. J Clin Oncol. 1990;8(11):1913-1921.
2. Warrell RP Jr, de Thé H, Wang ZY, Degos L. Acute promyelocytic leukemia. N Engl J Med. 1993;329(3):177-189.
3. Davey FR, Davis RB, MacCallum JM, et al. Morphologic and cytochemical characteristics of acute promyelocytic leukemia. Am J Hematol. 1989;30(4):221-227. (Pubitemid 19087311)
4. Larson RA, Kondo K, Vardiman JW, Butler AE, Golomb HM, Rowley JD. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am J Med. 1984;76(5):827-841. (Pubitemid 14142683)
5. Mertelsmann R, Tzvi TH, To L, et al. Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia. Blood. 1980;56(5):773-781. (Pubitemid 11242967)
6. Ventura GJ, Hester JP, Dixon DO, Khorana S, Keating MJ. Analysis of risk factors for fatal hemorrhage during induction therapy of patients with acute promyelocytic leukemia. Hematol Pathol. 1989;3(1):23-28. (Pubitemid 19178055)
7. Tallman MS, Lefebvre P, Baine RM, et al. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. J Thromb Haemost. 2004;2(8):1341-1350. (Pubitemid 40186131)
8. Grignani F, Fagioli M, Alcalay M, et al. Acute promyelocytic leukemia: from genetics to treatment. Blood. 1994;83(1):10-25. (Pubitemid 24016510)
9. Zelent A. Translocation of the RAR alpha locus to the PML or PLZF gene in acute promyelocytic leukaemia. Br J Haematol. 1994;86(3):451-460. (Pubitemid 24199031)
10. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337(15):1021-1028. (Pubitemid 27430519)
11. Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1999;94(4):1192-1200. (Pubitemid 29380399)
12. Sanz MA, Lo Coco F, Martin G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96(4):1247-1253. (Pubitemid 30658450)
13. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113(9):1875-1891.
14. Sanz MA, Martin G, Gonzalez M, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004;103(4):1237-1243. (Pubitemid 38168633)
15. Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89(9):3354-3360. (Pubitemid 27229822)
16. Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998;339(19):1341-1348. (Pubitemid 28509343)
17. Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19(18):3852-3860. (Pubitemid 32880064)
18. Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990;8(5):813-819.
19. Friedlin B, Korn EL, George SL. Data monitoring committees and interim monitoring guidelines. Controlled Clin Trials. 1999;20:395-407.
20. Barbey JT, Pezzullo JC, Soignet SL. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol. 2003;21(19):3609-3615. (Pubitemid 46594053)
21. Sanz MA, Montesinos P, Vellenga E, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. Blood. 2008;112(8):3130-3134.
22. Lo Coco F, Avvisati G, Vignetti M, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation: results of the AIDA-2000 trial of the Italian GIMEMA Group [abstract]. Am Soc Hematol Ann Meeting Abstr. 2004;104(11):392.
23. Ades L, Sanz MA, Chevret S, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood. 2008;111(3):1078-1084. (Pubitemid 351213385)
24. Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood. 1997;90(3):1014-1021.
25. Sanz MA, Martin G, Rayon C, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RAR-alpha-positive acute promyelocytic leukemia. PETHEMA group. Blood. 1999;94(9):3015-3021. (Pubitemid 29512705)
26. Mathews V, George B, Lakshmi KM, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006;107(7):2627-2632.
27. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol. 2006;17(1):131-134. (Pubitemid 43033852)
28. Hu J, Liu YF, Wu CF, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2009;106(9):3342-3347.
29. Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006;107(9):3469-3473.
30. Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-transretinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009;27(4):504-510.
31. Kelaidi C, Chevret S, de Botton S, et al. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. J Clin Oncol. 2009;27(16):2668-2676.
32. Ades L, Chevret S, Raffoux E, et al. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol. 2006;24(36):5703-5710. (Pubitemid 46631312)
33. Burnett AK, Hills RK, Grimwade D, et al. Idarubicin and ATRA is as effective as MRC chemotherapy in patients with acute promyelocytic leukaemia with lower toxicity and resource usage: preliminary results of the MRC AML15 trial [abstract]. Am Soc Hematol Ann Meeting Abstr. 2007;110(11):589.